Primary Sjogren's Syndrome Clinical Trial
Official title:
A Phase Ⅲ, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome
The purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.
This is a phase Ⅲ, multi-center, randomized, placebo-controlled, study. Subjects with active primary Sjogren's Syndrome (pSS) will be randomized to receive subcutaneous Telitacicept 80 mg, Telitacicept 160 mg or placebo weekly for a total of 48 weeks. Subjects are allowed to be transferred to another group after Week 24 by the investigator so that those randomized to the placebo group are able to receive either Telitacicept 80 mg or Telitacicept 160 mg afterwards. Subjects who are randomized to Telitacicept 80 mg and Telitacicept 160 mg groups will remain in the previous treatment group even if the investigator chooses to transfer them. Subjects and investigators are blinded throughout the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT00920179 -
Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome
|
N/A | |
| Recruiting |
NCT04544722 -
Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD
|
N/A | |
| Withdrawn |
NCT02027298 -
Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study
|
Phase 2 | |
| Withdrawn |
NCT05781451 -
Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
|
Phase 2 | |
| Withdrawn |
NCT04563195 -
BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00542763 -
Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome
|
Phase 1 |